Stockscreener 앱 받기
1.68
4.00%
-0.07
시간 외 거래:
1.70
0.02
+1.19%
전일 마감가:
$1.75
열려 있는:
$1.94
하루 거래량:
572.28K
Relative Volume:
0.07
시가총액:
$7.62M
수익:
$6.16M
순이익/손실:
$-14.91M
주가수익비율:
-0.1575
EPS:
-10.6693
순현금흐름:
$-9.39M
1주 성능:
+1.82%
1개월 성능:
-23.29%
6개월 성능:
+17.48%
1년 성능:
-78.68%
1일 변동 폭
$1.63
$2.175
1주일 범위
$1.5819
$2.175
52주 변동 폭
$0.693
$13.80
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
명칭
Bioaffinity Technologies Inc
전화
210-698-5334
주소
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
1.68 | 7.94M | 6.16M | -14.91M | -9.39M | -10.67 |
TMO
Thermo Fisher Scientific Inc
|
482.08 | 183.60B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
176.11 | 127.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
550.82 | 44.71B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.05 | 38.38B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
371.93 | 37.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Bioaffinity Technologies Inc 주식(BIAF)의 최신 뉴스
Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar - BioSpace
bioAffinity webinar to showcase CyPath Lung's role in early-stage lung cancer detection - TradingView
bioAffinity Technologies (BIAF) spotlights CyPath Lung test in SAB lung cancer webinar - Stock Titan
BIAF Q3 2025 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentManagement Guidance Update - thelegaladvocate.com
bioAffinity Technologies (BIAFW) Short Interest & Short Float | Updated May 2026 - MarketBeat
BIAF News | BIOAFFINITY TECHNOLOGIES INC (NASDAQ:BIAF) - ChartMill
bioAffinity receives patent allowance in Mexico for lung test - Investing.com UK
bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology - BioSpace
bioAffinity receives patent allowance in Mexico for lung test By Investing.com - Investing.com Nigeria
bioAffinity Technologies notifies Mexico patent allowance for CyPath® Lung flow cytometry method - TradingView
Mexico backs bioAffinity (NASDAQ: BIAF) patent on CyPath Lung test - Stock Titan
bioAffinity Technologies (BIAF) News Flow - Moomoo
Number of shareholders of bioAffinity Technologies, Inc. – NASDAQ:BIAF - TradingView
What's Driving bioAffinity Technologies' Recent Surge - Kavout
Top AIAI (AIAI) Competitors 2026 - MarketBeat
bioAffinity Technologies Inc (BIAF) Stock Price, Quote, News & History - Benzinga
BIAF Stock Price, Quote & Chart | BIOAFFINITY TECHNOLOGIES INC (NASDAQ:BIAF) - ChartMill
bioAffinity Technologies, Inc.Warrant (NQ: BIAFW - FinancialContent
bioAffinity (BIAF) registers 497,483 resale shares, includes 365,603 warrants - Stock Titan
BIAF Stock Slips Post Q1 Earnings Despite Strength in CyPath Lung - The Globe and Mail
[EFFECT] bioAffinity Technologies, Inc. SEC Filing - Stock Titan
bioAffinity reports 300% jump in lung test sales in April - Investing.com UK
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Ye - PharmiWeb.com
bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 - 01net
bioAffinity Technologies Reports Record 300% Growth in CyPath® Lung Diagnostic Test Sales in April 2026 - Minichart
bioAffinity CyPath Lung Test Sales Surge Sharply - TipRanks
TradingKey - TradingKey
bioAffinity reports 300% jump in lung test sales in April By Investing.com - Investing.com Australia
bioAffinity Reports Record Monthly CyPath Lung Unit Sales, April Up Nearly 300% - TradingView
Record CyPath Lung growth at bioAffinity (NASDAQ: BIAF) with April unit sales up nearly 300% - Stock Titan
bioAffinity Technologies, Inc. 2026 Q1 10-Q Filing: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
bioAffinity Technologies reports net loss of USD 3.6M in Q1 2026 - Medical Buyer
bioAffinity Technologies, Inc. 1Q 2026: Revenue $1.35M, EPS $(0.81) — 10-Q Summary - TradingView
BioAffinity Technologies : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Number of shareholders of bioAffinity Technologies, Inc. – NASDAQ:BIAFW - TradingView
BIAFW bioAffinity reports quarterly results with no revenue or earnings data disclosed; investors await further details.Estimate Uncertainty - thelegaladvocate.com
Q1 2026 loss deepens at bioAffinity Technologies (NASDAQ: BIAF) - Stock Titan
bioAffinity Technologies Releases Q1 2026 Financial Results - AlphaStreet
BIAF | bioAffinity Technologies, Inc. Common Insider Trading - Quiver Quantitative
bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung - BioSpace
Bioaffinity Technologies IncQ1 2026 net loss $3.6 million or $0.81 per share - marketscreener.com
BioAffinity Technologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CyPath Lung growth stands out in bioAffinity (NASDAQ: BIAF) Q1 2026 results - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
bioAffinity Shareholders Approve Equity Plan and Capital Measures - The Globe and Mail
Bioaffinity Technologies Inc (BIAF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
1.15%
자본화:
|
볼륨(24시간):